The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma

K Troppan¹, A Deutsch¹, A Gerger², T Stojakovic³, C Beham-Schmid⁴, K Wenzl¹, P Neumeister¹ and M Pichler *,²

¹Division of Hematology, Department of Internal Medicine, Medical University of Graz (MUG), Graz, Austria; ²Division of Oncology, Department of Internal Medicine, Medical University of Graz (MUG), Graz, Austria; ³Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz (MUG), Graz, Austria and ⁴Institute of Pathology, Medical University of Graz (MUG), Graz, Austria

Background: With growing evidence on the role of inflammation in cancer biology, the systemic inflammatory response has been postulated as having prognostic significance in a wide range of different cancer types. Recently, the derived neutrophil to lymphocyte ratio (dNLR) has been proposed as an easily determinable prognostic factor in cancer patients. Nevertheless, its prognostic significance in diffuse large B-cell lymphoma (DLBCL) patients has never been explored.

Methods: Data from 290 consecutive DLBCL patients, diagnosed between 2004 and 2013 at a single Austrian centre, were evaluated retrospectively. The prognostic influence of the dNLR and other clinico-pathological factors including age, lactate dehydrogenase, cell of origin category and Ann Arbor stage on 5-year overall- (OS) and disease-free (DFS) survival was studied by Kaplan–Meier curves. To evaluate the independent prognostic relevance of dNLR, univariate and multivariate Cox regression models were applied.

Results: An independent significant association between high dNLR and poor clinical outcome in multivariate analysis for OS (HR = 2.02, confidence interval (CI) 95% = 1.17–3.50, P = 0.011), as well as DFS (HR = 2.15, CI 95% = 1.04–4.47, P = 0.038), was identified.

Conclusion: In the present study, we showed that a high dNLR at diagnosis of DLBCL represents an independent poor prognostic factor for clinical outcome. Our data encourage the further validation of this easily available parameter in prospective studies and as a potential stratification tool in clinical trials.

Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring form of lymphoma, accounting for 30–40% of newly diagnosed non-Hodgkin’s lymphomas (NHL). With standard immunochemotherapy, DLBCL, even when in advanced stage, is considered a curable disease. Nevertheless, despite the improvements in therapy, approximately one-third of patients with advanced-stage DLBCL will still be refractory to therapy or will relapse (Friedberg, 2011).

Historically, clinicians and investigators have relied on prognostic schemes that imply clinical risk factors to predict the risk for disease progression, relapse and death of patients with aggressive NHL. One of the most commonly used schemes of rating, the International Prognostic Index (IPI) for lymphomas, developed in the 1990s, remains a robust clinical prognostic index for aggressive lymphomas. It involves five features: age, tumour stage, serum lactate dehydrogenase (LDH) concentration, performance status...
and number of extranodal disease sites. The IPI distinguishes four risk groups with different 5-year overall survival (OS), ranging from 26 to 73% (Shipp et al, 1993). In the era of Rituximab, a revised IPI (R-IPI) has been introduced, showing superior prediction in the outcome of DLBCL. Patients, treated with standard immunochemotherapy. The R-IPI identifies three distinct prognostic groups, with a very good (4-year OS 94%), good (OS 79%) and poor (OS 55%) outcome, respectively (Sehn et al, 2007). Nevertheless, a large group of patients with distinct clinicopathological profile and unfavourable outcome remains uncharacterized. Today, aside from clinical aspects, an additional distinction exists by the use of gene profiling, identifying two different subtypes, stratified by different survival times (Alizadeh et al, 2000). Genome-wide molecular profiling has revealed these subtypes of aggressive lymphoma, with tumour cells arising from different lymphoid maturation stages and usage of different oncogenic pathways. Patients with germinal center B-cell-like (GCB) DLBCL have a 5-year survival rate of 60%, as compared with a rate of less than 40% for patients with activated B-cell-like (ABC) DLBCL (Rosenwald et al, 2002). The crucial biological mechanisms that contribute to tumour development and further progression are not fully understood and more reliable and easy applicable prognostic factors, for individual risk assessment, have to be identified.

Inflammation has been identified to be a critical component of tumour progression, highlighting the role of the microenvironment, which is largely orchestrated by inflammatory cells as an indispensable participant in the neoplastic process, fostering proliferation, survival and migration (Cousens and Werb, 2002). For different solid tumours, as well as lymphomas, inflammation parameters, including leukocytes, neutrophils, lymphocytes and C-reactive protein, have been associated with higher mortality rates (Mohri et al, 2010; Cao et al, 2012).

In addition to absolute counts of inflammation parameters, also the neutrophil to lymphocyte ratio (NLR) has been identified as an independent prognostic factor for OS and progression free survival (PFS) in various types of cancer, including renal cell carcinoma, colorectal cancer, sarcoma and pancreatic cancer (Walsh et al, 2005; Zhang et al, 2012; Pichler et al, 2013a; Szakandera et al, 2013a). Recently, the NLR has been suggested to be a simple, inexpensive, standardized prognostic factor to assess clinical outcomes in DLBCL patients treated with R-CHOP (Porrata et al, 2010). Frequently, the absolute lymphocyte count is not routinely documented in clinical trials despite determining a differential white cell count. To solve this problem, the derived neutrophil to lymphocyte ratio (dNLR) was recently implemented, consisting of neutrophil count divided by (leukocyte count—neutrophil count) (Proctor et al, 2012). In this study by Proctor et al (2012), they proposed a similar prognostic value of the dNLR compared with the NLR in different solid cancer types but not explicitly for DLBCL patients. However, for hematological malignancies, the dNLR has not been validated yet. In the present study, therefore, we evaluated for the first time the prognostic significance of baseline dNLR in a large cohort of 290 patients, diagnosed with DLBCL.

**MATERIALS AND METHODS**

This retrospective analysis included data from 290 consecutive patients who were diagnosed with DLBCL according to the 2008 World Health Organization (WHO) (Campo et al, 2011) criteria at the Division of Hematology at the Medical University of Graz between January 2004 and April 2013. All of the clinicopathological data were retrieved from medical records from the Division of Hematology as well as from pathology reports from the Institute of Pathology at the same institution. Clinicopathological parameters included histologically confirmed DLBCL, gender, age, Ann Arbor stage and cell of origin categories (GCB and ABC subtype according to the Hans algorithm (Hans et al, 2004)). The laboratory data, including leukocyte, neutrophil and lymphocyte counts, were obtained by pre-diagnosis exploration 1–7 days before histologically proven diagnosis. Patients were treated by standard rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) regimen every 3 weeks for six to eight cycles. We do not routinely use combination radio-immunchemotherapy in early stage patients. According to the current ESMO guidelines, early stage lymphoma patients without bulky disease receive six cycles of R-CHOP every 3 weeks. Only patients with bulky disease are considered to treat with R-CHOP 21 × 6 with radiotherapy to the sites of previous bulky disease (Tilly et al, 2012). Post-treatment surveillance included routine clinical and laboratory examination. Regarding imaging methods, computer tomography was predominantly used. Follow-up evaluations were performed every 3 months during the first 5 years and annually thereafter. Patients were excluded in case of seropositivity of human immunodeficiency virus (HIV), missing laboratory parameters at diagnosis, lost to follow-up or central nervous system lymphoma. Dates of death were obtained from the central registry of the Austrian Bureau of Statistics or by telephone calls to their relatives. Overall survival was defined as the time (in months) from date of diagnosis until death due to any cause within the follow-up period. Disease-free survival was defined as the time (in months) from the date of the diagnosis to the date of demonstration of recurrent disease, confirmed radiologically or histologically. Disease-free survival was censored at the time of death or at the last follow up if the patients remained tumour free at that time. The study was approved by the local ethical committee of the Medical University of Graz.

**Statistical analyses.** The primary end point of the study was OS; the secondary end point was DFS. The optimal cutoff value for the dNLR was determined by applying receiver operating curve (ROC) analysis as previously described (Absenger et al, 2013). The cutoff value that discriminated best (in mean of sensitivity and specificity) between survival and death was used for OS. The cutoff value that discriminated best between disease-recurrence and no recurrence was used for DFS. The association between the dNLR with OS and DFS was analyzed using Kaplan–Meier curves and compared by the log-rank test. Backward stepwise multivariate Cox proportional analysis was performed to determine the influence of clinicopathological variables, significantly associated with clinical outcome in univariate analysis of OS and DFS. Hazard ratios (HRs) and the corresponding 95% CIs were estimated from the Cox regression analysis. The assumption of proportional hazards was checked by LML-Plots and residual analysis using Schoenfeld plots. All statistical analyses were performed using the Statistical Package for Social Sciences version 17.0 (SPSS Inc., Chicago, IL, USA). A two-sided P < 0.05 was considered statistically significant.

**RESULTS**

Overall, there were 137 (47.2%) male and 153 (52.8%) female patients diagnosed with DLBCL. The mean age at diagnosis was 65.5 ± 15.5 years. The Ann Arbor tumour stage was defined as stage I in 76 (26.2%) patients, stage II in 78 (26.9%) patients, stage III in 61 (21.0%) patients and stage IV in 75 (25.9%) patients. Extranodal disease was diagnosed in 128 (44.1%) patients. Eighty-nine patients featured histologically confirmed GCB subtype, 135 were identified as ABC subtype and 66 were unclassifiable/non-determined. Regarding the R-IPI, 21 (7.2%) had a very good R-IPI, 158 (54.5%) had a good R-IPI and 111 (38.3%) patients were...
The derived neutrophil-lymphocyte ratio in DLBCL

**Table 1. Univariate and multivariate Cox proportional of clinico-pathological parameters for the prediction of OS in patients with diffuse large B-cell lymphoma (n = 290)**

| Parameter                  | Five-year OS | Univariate analysis | Multivariate analysis |
|----------------------------|--------------|---------------------|-----------------------|
|                            | No. at risk  | No. events | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Age at diagnosis (years)   |              |           |             |         |             |         |
| < 60                       | 86           | 10        | 1 (Referent) |         | <0.001      | 1 (Referent) | 0.047 |
| ≥ 60                       | 204          | 75        | 3.82 (1.97–7.4) |         | 3.52 (1.48–8.35) |         |
| Clinical stage (Ann Arbor) |              |           |             |         |             |         |
| I and II                   | 154          | 31        | 1 (Referent) | <0.001 | 1 (Referent) | 0.012 |
| III and IV                 | 136          | 54        | 2.43 (1.56–3.78) |         | 2.38 (1.21–4.68) |         |
| LDH                        |              |           |             |         |             |         |
| Normal                     | 83           | 14        | 1 (Referent) |         | 1 (Referent) | 0.160 |
| > 200 U l⁻¹                | 204          | 71        | 2.42 (1.36–4.29) |         | 1.62 (0.83–3.16) |         |
| Cell of origin             |              |           |             |         |             |         |
| GCB                        | 89           | 15        | 1 (Referent) |         | 1 (Referent) | 0.007 |
| non GCB                    | 135          | 50        | 2.49 (1.4–4.43) |         | 2.25 (1.25–4.04) |         |
| dNLR                       |              |           |             |         |             |         |
| < 4                        | 236          | 63        | 1 (Referent) |         | 1 (Referent) | 0.011 |
| ≥ 4                        | 54           | 22        | 1.64 (1.01–2.66) |         | 2.03 (1.17–3.5) |         |
| Gender                     |              |           |             |         |             |         |
| Female                     | 153          | 41        | 1 (Referent) |         | 0.544       | n.d.    |
| Male                       | 137          | 44        | 1.07 (0.86–1.32) |         | n.d.        | n.d.    |

Abbreviations: CI = confidence interval; dNLR = derived neutrophil to lymphocyte ratio; GCB = germinal center B cell; HR = hazard ratio; n.d. = not done; No. at risk = number of individuals at risk; No. events = number of outcome events; OS = overall survival.
high tumour stage (Stage I + II vs stage III + IV, \( P < 0.001 \)), elevated LDH levels (normal vs \( > 200 \text{Ul}^{-1} \), \( P = 0.003 \)), cell of origin (GCB vs ABC, \( P = 0.002 \)) and high dNLR (\( < 4 \) vs \( \geq 4 \), \( P = 0.047 \)) as prognosticators of poor outcome for patients’ OS, whereas gender and extranodal disease were not statistically significant associated with OS (Table 1).

To determine the independent prognostic value of the dNLR for OS, a multivariate analysis using a Cox proportional hazard model was performed. In the multivariate analysis, which included all independent parameters significantly associated with clinical outcome in univariate analysis (age, tumour stage, LDH, cell of origin and dNLR), we identified age (\( P = 0.004 \)), tumour stage (\( P = 0.012 \)), cell of origin (\( P = 0.007 \)) and high dNLR (\( P = 0.011 \)) as independent prognostic factors for OS, whereas elevated LDH was not significantly associated with OS (Table 1).

Regarding DFS, we calculated for the dNLR a cutoff value of 1.8 to be optimal to discriminate between DFS and recurrence state. Figure 2 shows the Kaplan–Meier curves for 5-year DFS and reveals that a dNLR \( \geq 1.8 \) is a significant factor for shorter 5-year DFS in DLBCL patients (\( P < 0.032 \), log-rank test). To determine the independent prognostic significance of the new established cutoff value of dNLR for DFS, a multivariate Cox proportional hazard model including all parameters significantly associated with DFS in univariate analysis (see Table 2) was calculated. In the multivariate analysis, we identified age (\( P = 0.028 \)), tumour stage (\( P = 0.013 \)), cell of origin (\( P = 0.008 \)) and the dNLR (\( P = 0.038 \)) as independent prognostic factors for DFS (Table 2).

Finally, we found a weak but significantly negative correlation between dNLR and monocyte count (\( R = -0.136, P = 0.021 \), Spearman correlation). We calculated for the monocyte count a

Table 2. Univariate and multivariate analysis of clinico-pathological parameters for the prediction of DFS in patients with diffuse large B-cell lymphoma (\( n = 290 \))

| Parameter               | No. at risk | No. events | HR (95% CI)       | P-value | HR (95% CI)       | P-value |
|-------------------------|------------|------------|-------------------|---------|-------------------|---------|
| Age at diagnosis (years)|            |            |                   |         |                   |         |
| < 60                    | 86         | 13         | 1 (Referent)      | 0.02    | 1 (Referent)      | 0.028   |
| \( \geq 60 \)           | 204        | 51         | 2.06 (1.12–3.79)  |         | 2.48 (1.11–5.58)  |         |
| Clinical stage (Ann Arbor) |     |            |                   |         |                   |         |
| I and II                | 154        | 24         | 1 (Referent)      | 0.001   | 1 (Referent)      | 0.013   |
| III and IV              | 136        | 40         | 2.42 (1.46–4.02)  |         | 2.6 (1.22–5.54)   |         |
| LDH                     |            |            |                   |         |                   |         |
| Normal                  | 83         | 10         | 1 (Referent)      | 0.004   | 1 (Referent)      | 0.083   |
| \( > 200 \text{U}l^{-1} \) | 204        | 54         | 2.67 (1.36–5.25)  |         | 2.01 (0.91–4.43)  |         |
| Cell of origin          |            |            |                   |         |                   |         |
| GCB                     | 89         | 12         | 1 (Referent)      | 0.008   | 1 (Referent)      | 0.008   |
| non GCB                 | 135        | 36         | 2.42 (1.26–4.66)  |         | 2.43 (1.26–4.67)  |         |
| dNLR                    |            |            |                   |         |                   |         |
| \( < 1.8 \)             | 91         | 12         | 1 (Referent)      | 0.036   | 1 (Referent)      | 0.038   |
| \( \geq 1.8 \)          | 198        | 52         | 1.96 (1.04–3.67)  |         | 2.16 (1.04–4.47)  |         |
| Gender                  |            |            |                   |         |                   |         |
| Female                  | 153        | 28         | 1 (Referent)      | 0.183   | n.d.              | n.d.    |
| Male                    | 137        | 36         | 1.18 (0.92–1.51)  |         | n.d.              | n.d.    |

Abbreviations: CI = confidence interval; DFS=disease-free survival; dNLR=derived neutrophil to lymphocyte ratio; GCB=germinal center B cell; HR=hazard ratio; n.d. = not done; No. at risk = number of individuals at risk; No. events = number of outcome events; OS= overall survival.
cutoff value of 700 mm$^{-3}$ as optimal for discrimination of OS. This cutoff value is very similar to a study by Tadmor et al (2013) (630 mm$^{-3}$) who demonstrated a prognostic role for monocyte count in DLBCL patients. To test whether monocyte count is also an independent prognostic value in our cohort, we calculated a multivariate Cox model that also includes the monocyte count as a prognostic variable. Importantly, we found a statistically significant prognostic meaning for both, the dNLR ($P = 0.004$) and the monocyte count ($P = 0.038$, HR = 1.75 95% CI = 1.03–2.9), indicating that both parameters add independent prognostic information to well-established prognosticators.

**DISCUSSION**

In this study, we validated for the first time the prognostic value of dNLR in a large cohort of DLBCL patients. Univariate analysis as well as multivariate analysis identified dNLR as a prognostic factor of 5-year OS and 5-year DFS.

In general, inflammatory processes have been identified as critical components of tumour progression (Cousens and Werb, 2002). Inflammatory cells can release growth and survival factors, promoting angiogenesis and lymphangiogenesis, stimulate DNA damage and promote tumour evasion of the host defense mechanisms (De Visser et al, 2006). Although the inflammatory response can be expected to have tumour suppressive actions, cancer patients often lack sufficient inflammatory response (Finn, 2012). In various types of cancers, for example, breast cancer, melanoma and lymphoma, innate immune cells like granulocytes, macrophages and mast cells correlate with increased angiogenesis and/or poor prognosis, which is in part explained by upregulation of cyclooxygenase-2 or suppression of anti-tumour adaptive immune response (Leek et al, 1996; Liu et al, 2001; Schoppmann et al, 2002; Dannenberg and Subbaramaiah, 2003; Ribatti et al, 2003). On the other hand, infiltrating lymphocytes are associated with favourable prognosis which was recently shown in non-small cell lung cancer and ovarian cancer (Sato et al, 2005; Horne et al, 2011). The adaptive immune cells such as B-lymphocytes, CD4 + helper T-lymphocytes and CD8 + cytotoxic T-lymphocytes modulate cancer development via cytokine-mediated lysis of tumour cells or establishing a pro-inflammatory state in the tumour microenvironment, revealing the paradoxical role of adaptive and innate leukocytes as crucial opposing regulators in cancer development (Ishigami et al, 2000; Zou, 2005).

The critical role of B-lymphocytes in initiating chronic inflammation during pre-malignancy has already been demonstrated by De Visser et al (2005). In a tumour-prone mouse model deficient in B and T cells, adoptive transfer of B-lymphocytes restores innate immune cell infiltration into pre-malignant tissue and reinstates necessary parameters for full malignancy. These findings support the hypothesis in which B-lymphocytes are required for establishing chronic inflammatory states that promote de novo carcinogenesis. Further, in a murine model, a subset of regulatory B-cells was recently found to inhibit anti-CD20 immunotherapy-mediated lymphoma depletion through the production of interleukin-10, a potent regulator of inflammation and autoimmune immune responses. Even if present in small amount, they negatively influence effector functions of monocytes and in consequence, the lymphoma response to antibody-targeted therapy (Horikawa et al, 2011). However, despite the substantial progress and novel insights into lymphomagenesis during the past years, clinicians also require fast and easily measurable tools as indicators for patient survival. Within the last recent years, the systemic inflammatory response has been identified as an important driver of cancer progression in different types of cancer (Proctor et al, 2011a).

Different laboratory parameters including the modified Glasgow prognosis score (Proctor et al, 2011b), the neutrophil-lymphocyte ratio, the platelet-lymphocyte ratio, the C-reactive protein or fibrinogen levels (Pichler et al, 2013b) have been proposed as prognostic parameters that adequately reflect this systemic inflammatory response. However, there is plenty of clinical trial data, where only leukocyte and lymphocyte counts have been recorded. To overcome the lacking data, Proctor et al (2012) developed the dNLR and demonstrated the non-inferiority to the NLR in a large cohort of patients with different types of cancer. As the dNLR is mainly derived from the count of neutrophils and lymphocytes, our study also supports the potential of widespread use of this biomarker as a surrogate for inflammatory response.

Importantly, the variation over time and factors that might influence the dNLR have to be discussed. In general, the NLR (and also the dNLR) is supposed to reflect the systemic inflammatory response that accompanies chronic diseases, but might also be influenced by many different factors, including systemic infections, atherosclerosis, hypertension, chronic renal diseases and diabetes and can be even affected by atherosclerotic risk factors and drug treatment (Szkandera et al, 2013b). In our study, the previously published cutoff value of 2, as proposed in the study of Proctor et al (2012), showed no prognostic information in our cohort. The reasons for this discordance might be explained by the missing information in their study. In their original report about the dNLR, Proctor et al (2012) reported data from the Scottish cancer registry including hematological cancers. However, they did not separately analyze different hematological cancer entities. Moreover, they have no data for important prognostic variables like stage or others, which were included in the multivariate model in our study cohort. However, our study was not without limitations. Although we used a strategy to separately determine the optimal cutoff value for each end point as previously reported (Absenger et al, 2013), these cutoff values have to be externally validated in independent cohorts, most preferable in a prospective manner.

In conclusion, although it warrants further validation in independent prospective studies, the dNLR is an easily available and inexpensive marker in clinical studies and routine and has shown considerable potential as new prognostic marker for patients with DLBCL.

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**REFERENCES**

The International Non-Hodgkin’s Lymphoma Prognostic Factor Project (1993) A predictive Model for aggressive Non-Hodgkin’s Lymphoma. N Engl J Med 329(14): 987–994.

Absenger G, Szkandera J, Pichler M, Stotz M, Armingen F, Weissmueller M, Schabberl-Moser R, Samonigg H, Stojakovic T, Gerger A (2013) A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer 109(2): 395–400.

Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769): 503–511.

Campano E, Swerdlov SH, Harris NL, Pileri S, Stein H, Jaffe ES (2011) WHO classification of tumours of hematopoietic and lymphoid tissues. Blood 117(19): 5019–5032.
Cao Y, Shi XY, Chen JQ, Tan YT, Cai YC, Luo HY, Qiu MZ, Cai XY, Jin Y, Sun YL, Jiang WQ (2012) Serum C-reactive protein as an important prognostic variable in patients with diffuse large B-cell lymphoma. *Tumour Biol* 33(4): 1039–1044.

Coussens LM, Werb Z (2002) Inflammation and cancer. *Nature* 420(6917): 860–867.

Dannenberg AJ, Subbaramaiah K (2003) Targeting cyclooxygenase-2 in human neoplasia: Rationale and promise. *Cell Cancer* 4(6): 431–436.

De Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. *Nat Rev Cancer* 6(1): 24–37.

De Visser KE, Korets LV, Coussens LM (2005) *De novo* carcinogenesis promoted by chronic inflammation: is B lymphocyte dependent. *Cancer Cell* 7(5): 411–423.

Finn OJ (2012) Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. *Ann Oncol* (Suppl 8): viii–vi9.

Friedberg JW (2011) New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice. *Clin Cancer Res* 17(19): 6112–6117.

Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood* 103(1): 275–282.

Horikawa M, Minard-Colin V, Matsushita T, Tedder TF (2011) Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. *J Clin Invest* 121(11): 4268–4280.

Horne ZD, Jack R, Gray ZT, Siegfried JM, Wilson DO, Yousem SA, Nason KS, Landreneau RJ, Lukitch JD, Schuchert MJ (2011) Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage IA non-small cell lung cancer. *J Surg Res* 171(1): 1–5.

Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, Aridome K, Nagy K, Alitalo K, Kerjaschki D (2002) Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. *Am J Pathol* 161(3): 947–956.

Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Ondusni T, Ritter G, Lele S, Chen YT, Ohtani H, Old JI, Ondusni K (2005) Intraperithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/CD5+ ratio are associated with favorable prognosis in ovarian cancer. *Proc Natl Acad Sci USA* 102(51): 18533–18543.

Schoppmann SF, Birner P, Stokk J, Kalt R, Ullrich R, Cauicq C, Kriehuber E, Nagy K, Alitalo K, Kerjaschki D (2002) Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. *Am J Pathol* 161(3): 947–956.

Szekandera J, Absenger G, Liegl-Atzwanger B, Pichler M, Stutz M, Samonigg H, Gehr M, Zacherl M, Stojakovic T, Gerger A, Leithner A (2013a) Elevated proepitope neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients. *Br J Cancer* 108(9): 1677–1683.

Szekandera J, Pichler M, Gerger A, Leithner A (2013b) Reply: comment on ‘Elevated proepitope neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients’. *Br J Cancer* 108(12): 2627.

Tadmor T, Bari A, Sacchi S, Marcheselli L, Liardo EV, Avizi I, Benyamin N, Attias D, Pozzi S, Cox MC, Baldini L, Bruguiarello M, Federico M, Prolla A (2013) Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 191 patients, in the pre and post rituximab era. *Haematologica;* e-pub ahead of print 13 September 2013; doi:10.3324/haematol.2013.088161.

Tilly H, Vitolo U, Walewski J, de Silva MG, Shpilberg O, Andre M, Pfundenschuh M, Dreyling M. on behalf of the ESMO Guidelines Working Group (2012) Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 23(Suppl 7): vii78–vii82.

Walsh SR, Cook EJ, Goulter F, Justin TA, Keeling NJ (2005) Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. *J Surg Oncol* 91(3): 181–184.

Zhang DS, Wang DS, Wang ZQ, Wang FH, Luo HY, Qiu MZ, Wang F, Li YH, Xu RH (2012) Comparison of the prognostic values of various inflammation-based factors in patients with pancreatic cancer. *Med Oncol* 29(5): 3092–3100.

Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. *Nat Rev Cancer* 5(4): 263–274.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.